Be on our

Show

To be a part of BuxMont Live Sign up Now!
icon-1
 

Promote your

Event

Tell Us and We’ll Read it On Air.

icon-3

Bring the

Music

Share your music on BuxMont Live radio

icon-4

NCCN Oncology Research Program to Oversee Trials of the FGFR Inhibitor Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology

Written by John Ralston on . Posted in Uncategorized

NCCN Oncology Research Program to Oversee Trials of the FGFR Inhibitor Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho OncologyPLYMOUTH MEETING, Pa., Jan. 27, 2020 /PRNewswire/ — The National Comprehensive Cancer Network(®) (NCCN(®)) Oncology Research Program (ORP) today announced plans to evaluate futibatinib (TAS-120), a potent and selective inhibitor of the fibroblast growth factor receptor (FGFR). The project will…

Tags: